Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579458 | 0.86 | LMNA (0.47) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL2539437 | 0.80 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL11115568 | 0.77 | RAB9A (0.51) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL903215 | 0.77 | LMNA (0.54) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL20377073 | 0.75 | MET (0.58) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL251663 | 0.74 | LMNA (0.45) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL12125640 | 0.73 | LMNA (0.66) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL10575793 | 0.70 | SMN1; SMN2 (0.60) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL10571493 | 0.70 | RAB9A (0.60) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL5818702 | 0.69 | RAB9A (0.58) | RAB9ASMN1; SMN2ALDH1A1NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321040-B2 | Triazolo-pyridines as anti-inflammatory compounds | PFIZER INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1601672-B1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1601672-A1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075365-A1 | Novel triazolo-pyridines as anti-inflammatory compounds | PFIZER, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004072072-A1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075365-A1 | Novel triazolo-pyridines as anti-inflammatory compounds | MAPK6, IL6, GRK6 | RAB9A 3667/4885SMN1; SMN2 2194/4885ALDH1A1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.